CN113646330A - 工程化cd25多肽及其用途 - Google Patents

工程化cd25多肽及其用途 Download PDF

Info

Publication number
CN113646330A
CN113646330A CN201980088633.3A CN201980088633A CN113646330A CN 113646330 A CN113646330 A CN 113646330A CN 201980088633 A CN201980088633 A CN 201980088633A CN 113646330 A CN113646330 A CN 113646330A
Authority
CN
China
Prior art keywords
antibody
cdr
engineered
binding
engineered polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088633.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·格雷文
P·T·吉普
M·斯里尼瓦桑
A·莫里
K·E·豪瑟
J·R·威利斯
C·A·摩尔
C·巴雷特
A·T·田口
A·埃斯特莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yibio Co
Original Assignee
Rubik Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubik Therapy Co ltd filed Critical Rubik Therapy Co ltd
Publication of CN113646330A publication Critical patent/CN113646330A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980088633.3A 2018-11-14 2019-11-14 工程化cd25多肽及其用途 Pending CN113646330A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CN113646330A true CN113646330A (zh) 2021-11-12

Family

ID=70731914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088633.3A Pending CN113646330A (zh) 2018-11-14 2019-11-14 工程化cd25多肽及其用途

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585918A (zh) * 2019-05-31 2022-06-03 鲁比克治疗股份有限公司 中尺度工程化肽和选择方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
CN116745318A (zh) * 2020-11-10 2023-09-12 斯克里普斯研究学院 用于阿片样物质治疗的抗体
US20240096443A1 (en) * 2020-12-01 2024-03-21 Ibio, Inc. Generalized Scaffolds for Polypeptide Display and Uses Thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US20120276125A1 (en) * 2011-04-29 2012-11-01 Oliver Ast Novel immunoconjugates
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
CN107129524B (zh) 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016040110A1 (en) 2014-09-10 2016-03-17 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016179212A1 (en) 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CN110856446A (zh) * 2017-04-18 2020-02-28 阿法姆海外股份有限公司 抗pd-l1抗体及其用途
JP7464530B2 (ja) * 2018-03-28 2024-04-09 ブリストル－マイヤーズ スクイブ カンパニー インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
CA3120096A1 (en) 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
EP3976083A4 (en) 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US20120276125A1 (en) * 2011-04-29 2012-11-01 Oliver Ast Novel immunoconjugates
WO2018167104A1 (en) * 2017-03-17 2018-09-20 Tusk Therapeutics Ltd Fc-optimized anti-cd25 for tumour specific cell depletion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NH TRIER ET AL: "Production and characterization of peptide antibodies", METHODS, vol. 56, no. 2, pages 136 - 144, XP055294033, DOI: 10.1016/j.ymeth.2011.12.001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114585918A (zh) * 2019-05-31 2022-06-03 鲁比克治疗股份有限公司 中尺度工程化肽和选择方法

Also Published As

Publication number Publication date
US20230016112A1 (en) 2023-01-19
WO2020102603A1 (en) 2020-05-22
JP2022513043A (ja) 2022-02-07
JP2025026923A (ja) 2025-02-26
JP2026065087A (ja) 2026-04-14
US12441803B2 (en) 2025-10-14
EP3880698A4 (en) 2022-11-30
CA3120102A1 (en) 2020-05-22
JP7695881B2 (ja) 2025-06-19
EP3880698A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
US20220081472A1 (en) Meso-scale engineered peptides and methods of selecting
US20040110226A1 (en) Antibody optimization
JP6391574B2 (ja) 種間標的内交差反応性を有する抗体分子を産生する方法
CN114746440A (zh) 新型多肽复合物
RU2639505C2 (ru) Библиотека fv на основе комбинаций белков и способ ее получения
JP7217772B2 (ja) 三次元構造に基づくヒト化方法
CA2915956A1 (en) Rational method for solubilising proteins
CN118702814A (zh) 一种抗ngf单克隆抗体及其应用
Luthra et al. Human antibody bispecifics through phage display selection
JP7691234B2 (ja) 抗体の抗原に対する親和性を向上させる方法及びその利用
HK40063514A (en) Engineered cd25 polypeptides and uses thereof
CN113677691A (zh) 选择功能界面模拟物的方法及其组合物
Team et al. Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
JP2024523921A (ja) 特異的バインダーの選択手段及び方法
CN101426526B (zh) 使用工程诱杀蛋白的液相生物淘选方法
Chen et al. Improved isolation of anti-rhTNF-α scFvs from phage display library by bioinformatics
Rodríguez Gómez et al. Generation and NGS profiling of naïve rabbit antibody libraries for efficient monoclonal antibody selection
Pszolla Computational design of novel interactions in conventional and heavy chain antibodies
HK40098558A (zh) 基於三维结构的人源化方法
CN117836308A (zh) 用于选择特异性结合剂的手段和方法
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
HK40076302B (zh) 新型多肽复合物
HK40023878B (zh) 基於三维结构的人源化方法
HK1132177B (en) Solution phase biopanning method using engineered decoy proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063514

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230216

Address after: Texas, USA

Applicant after: Yibio Co.

Address before: California, USA

Applicant before: Rubik therapy Co.,Ltd.